Minimal Vitrectomy Surgery for Epiretinal Membrane
Minimal Vitrectomy Surgery (MVS) Versus Conventional Vitrectomy for the Treatment of Idiopathic Epiretinal Membrane: A Multicenter Randomized Controlled Trial
Peking Union Medical College Hospital
140 participants
Dec 1, 2024
INTERVENTIONAL
Conditions
Summary
This multicenter randomized controlled trial evaluates Minimal Vitrectomy Surgery (MVS) versus conventional vitrectomy for idiopathic epiretinal membrane (ERM). The primary endpoints include visual acuity improvement and cataract progression after 12 months. MVS aims to minimize vitreous removal while ensuring complete membrane removal through adaptive limited vitrectomy.
Eligibility
Inclusion Criteria5
- Age ≥ 18 years.
- Diagnosis of idiopathic epiretinal membrane (ERM) confirmed by clinical examination and OCT imaging.
- Clear ocular media allowing adequate fundus imaging.
- Phakic eye.
- Ability and willingness to provide written informed consent.
Exclusion Criteria3
- Prior cataract surgery or advanced cataract requiring combined surgery. Co-existing retinal diseases (e.g., diabetic retinopathy, retinal detachment, retinal vein occlusion).
- Systemic conditions preventing safe surgery or follow-up.
- History of prior ocular or periocular corticosteroid use, including intraocular injection, periocular injection, or long-term topical corticosteroid eye drops.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The epiretinal membrane is peeled directly through the intact vitreous. Limited localized vitrectomy is selectively performed if pre-existing floaters or membrane fragments remain after peeling.
Standard pars plana vitrectomy is performed with posterior vitreous detachment induction and core vitreous removal prior to epiretinal membrane peeling.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07019896